IRIS

Prochloraz

CASRN 67747-09-5

Noncancer Assessment

Reference Dose for Oral Exposure (RfD) (PDF) (13 pp, 114 K) last updated: 01/01/1989

System RfD (mg/kg-day) Basis PoD Composite UF Confidence
Hepatic 9 x 10-3 Increase in SAP and liver weights, liver histopathology NOEL : 9.0 x 10-1
mg/kg-day
100 High

 


Reference Concentration for Inhalation Exposure (RfC) (PDF) (13 pp, 114 K)
Not assessed under the IRIS Program.

 

Cancer Assessment

Weight of Evidence for Cancer (PDF) (13 pp, 114 K) last updated: 10/01/1989

WOE Characterization Framework for WOE Characterization
C (Possible human carcinogen) Guidelines for Carcinogen Risk Assessment (US EPA, 1986)
Basis:
  • Statistically significantly increased incidence and dose-related trend in liver adenomas and carcinomas (combined) in both sexes of one strain of mouse.
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (13 pp, 114 K)

Oral Slope Factor: 1.5 x10 -1 per mg/kg-day
Drinking Water Unit Risk: 4.3 x10 -6 per µg/L
Extrapolation Method: Male mice: time-to-tumor linearized multistage procedure in dose, Weibull in time. Female mice: linearized multistage procedure
Tumor site(s): Hepatic
Tumor type(s): Liver adenoma/ carcinoma combined (Nor-Am Chemical Co., 1983)



Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (13 pp, 114 K)

Not Assessed under the IRIS Program.

You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.